Overweight (Downgrade Alert) We have been overweight the S&P biotech index and adding alpha to our portfolio in the double digits since February 2019. While a few technology sectors and subsectors have come close to vaulting to…
Highlights Portfolio Strategy The Fed’s extremely easy monetary backdrop along with easy fiscal policy remain the dominant macro themes, and they will continue to underpin the equity market. We remain constructive on the equity…
Biotech stocks are now in the recovery ward as the sector made a U-turn in early October and has been rallying ever since. The rebound coincides with the return of M&A activity following the dramatic 50% contraction since…
Overweight While our overweight call in the S&P biotech index is offside, it is more than offset by the concurrent underweight call we have on the S&P pharma index. But, biotech stocks are now in the recovery ward as…
We doubt the merger mania is over and we continue to believe that more mega deals are in store, either intra or inter-industry, with Big Pharma hungry and in a hurry to replenish their drug pipeline. From a long-term macro…
Overweight Biotech stocks have been the center of attention recently as the BMY/CELG deal put the whole sector in play, and yesterday we boosted exposure to overweight in the S&P biotech index. We doubt the merger mania…
Highlights Portfolio Strategy The path of least resistance is higher for the broad equity market on the back of a reflationary impulse and a less dogmatic Fed. Now that the SPX forward EPS bar has been lowered to the ground, upward…
Highlights The long term direction for the pound is higher... ...but as the EU withdrawal bill passes through the U.K. parliament, expect a very hairy ride. The stock markets in Norway, Sweden and Denmark are driven by energy,…